Major changes to Panadol are set to hit shelves ahead of a decision by the Therapeutic Goods Administration (TGA) to change the packaging of products containing paracetamol.
Last year, the TGA announced a series of changes to paracetamol packaging, stating that the maximum pack size available for general sale will drop from 20 capsules to 16.
The change will take effect starting February 2025 in places like supermarkets and convenience stores.
However, the size of packages available for sale in pharmacies without the supervision of a pharmacist will also be halved, from 100 tablets or capsules to 50.
Packages with up to 100 tablets or capsules will only be available under the supervision of a pharmacist, while capsules and tablets will only be available in blister packs.
The decision took into account an independent expert report commissioned by the TGA which found that rates of intentional self-poisoning with paracetamol have increased over the past decade, particularly among teenagers and young adults.
It also found that paracetamol is the most commonly used medication in overdoses among young Australians, with the figure stable at 50 per cent.
“To further minimize the harm from paracetamol overdose, the TGA is encouraging retailers, such as supermarkets, to restrict sales to a single pack at a time,” the TGA announcement states.
From February 2025, the maximum package size of Panadol available for general sale in supermarkets and convenience stores will be reduced from 20 tablets to 16.
In pharmacies without the supervision of a pharmacist, the container size will drop from 100 tablets or capsules to 50
‘The TGA also encourages consumers not to stockpile paracetamol at home and to properly store paracetamol and other medicines.
“To give manufacturers and retailers enough time to adapt, the decision will take effect on February 1, 2025.”
Following the decision, Panadol began implementing the changes ahead of the February 2025 deadline.
Elena Pintado, head of pain at Haleon (the makers of Panadol), said there is no change in the “suitability and effectiveness profile of paracetamol for pain relief when used as directed” after the changes.
Painaustralia ambassador Sophie Scott (pictured) said paracetamol remains “effective” when used as directed.
‘Our focus is always on the health of Australians and facilitating responsible self-care. “As manufacturers of Panadol, Australia’s number one trusted pain relief brand, we take seriously our responsibility to ensure Australians can continue to access Panadol without interruption as these changes come into effect,” said Ms. Painted.
Painaustralia ambassador Sophie Scott said paracetamol remains “effective” when used as directed.
‘Everyday pain affects a large number of Australians and paracetamol is widely used to manage it. “Paracetamol is effective in relieving everyday pain when used as directed,” Ms Scott said.
“It is important that we follow the instructions on the packaging and consult a healthcare professional if our pain persists.”